Navigation Links
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
Date:7/24/2009

pical anesthetic as part of the Qutenza treatment procedure."

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Ref
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
4. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
5. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
(Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... March 16 Sigma-Aldrich® (Nasdaq: SIAL ) ... Ace Animals, Inc., a Berks County, PA. -based ... industry. Ace Animals ( www.aceanimals.com ), a commercial rodent ... contract breeding services, and will operate as part of ...
... , INDIANAPOLIS and MELBOURNE, Australia , ... (NYSE: LLY ) and Acrux (ASX: ACR) ... worldwide license agreement for the potential commercialization of Acrux,s ... drug application for AXIRON is currently under regulatory review ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 2Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 3Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 4Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 5
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on the ... legislature but which has not been signed to date by ... 449 with overwhelming bipartisan support on April 10, 2015, ... This bill ensures that fracking is prohibited in Maryland through ... of fracking to our water supplies and the air we ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... New York, New York (PRWEB) May 22, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals ... complications due to its use continue to move ... of Louisiana. According to a Pretrial Order dated ... governing the preservation of documents and electronically stored ...
Breaking Medicine News(10 mins):Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... could offer new treatments for other autoimmune disorders, study ... believe they have finally answered a basic question about ... body does the wheat protein gluten enter one,s system? ... Gastroenterology identifies the CXCR3 receptor in the ...
... July 24 Tepha, Inc., a developer of,medical ... polymers, announced,today that it has appointed John Hartnett ... Chief Operating Officer. Mr. Hartnett joins Tepha,following an ... he,progressed from field sales, to marketing management, and, ...
... (Becton,Dickinson and Company) (NYSE: BDX ) today reported ... quarter ended June 30, 2008,representing an increase of 14.5 ... rate reflects the favorable impact on all segments,from foreign ... 7 percentage points of the increase in quarterly revenues., ...
... Cancellations and Higher Operating Costs to Affect ... ... 7, 2008, DENVER, July 24 Air Methods Corporation,(Nasdaq: ... an update on second quarter 2008 results., Based on preliminary ...
... alliance of animal,lovers is attacking one of America,s most ... America is struggling with a weight problem. About ... Unfortunately, our pets -- they really,do look like us ... Campaign to End Obesity, a public/private partnership that includes,Harvard ...
... for its module cleanrooms. The feature is a utility panel ... cleanroom appearance. , ... Burnsville, Minn. (PRWEB) July 24, ... systems, announced today that they are now offering a utility panel ...
Cached Medicine News:Health News:Intestinal Gluten Receptor Is Gateway for Celiac Disease 2Health News:Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer 2Health News:BD Announces Results for Third Fiscal Quarter 2Health News:BD Announces Results for Third Fiscal Quarter 3Health News:BD Announces Results for Third Fiscal Quarter 4Health News:BD Announces Results for Third Fiscal Quarter 5Health News:BD Announces Results for Third Fiscal Quarter 6Health News:BD Announces Results for Third Fiscal Quarter 7Health News:BD Announces Results for Third Fiscal Quarter 8Health News:BD Announces Results for Third Fiscal Quarter 9Health News:BD Announces Results for Third Fiscal Quarter 10Health News:BD Announces Results for Third Fiscal Quarter 11Health News:BD Announces Results for Third Fiscal Quarter 12Health News:BD Announces Results for Third Fiscal Quarter 13Health News:BD Announces Results for Third Fiscal Quarter 14Health News:BD Announces Results for Third Fiscal Quarter 15Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 2Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 3Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 4Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2
Inquire...
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... The Eclipse TE2000S is ... live cell research. It's exclusive ... resolution with high numerical aperatures ... the first inverted microscope to ...
... IX71's modular frame and ... access ports for multiple ... Up to four ports ... to a primary image. ...
Medicine Products: